Department of Pharmacology and Toxicology

Dr. Anuradha S. Majumdar

Associate Professor & Head, Department of Pharmacology

Bombay College of Pharmacy, University of Mumbai

Former Dean, Faculty of Science & Technology, University of Mumbai

Editor, Pharma Times (2024–2026) | Chairperson, Institutional Animal Ethics Committee (IAEC)

Dr. Anuradha S. Majumdar
πŸ’Ό27+ YearsExperience
πŸ“„60+Publications
πŸ“š6 PatentsGranted
πŸ’°β‚Ή3+ CroreResearch Funding
Professional Overview
  • Distinguished academician and researcher with 27+ years in pharmacological sciences
  • Former Dean, Faculty of Science & Technology, University of Mumbai
  • Guided 100+ M.Pharm and 8 Ph.D. scholars
  • Strong focus on translational and interdisciplinary pharmacology
Research Areas
  • Mitochondrial & Energy Metabolism
  • Environmental Toxicology
  • Drug Delivery Systems
  • Neuropharmacology & Herbal Research
  • Herbal & Integrative Pharmacology
Academic & Administrative Leadership
  • Former Dean, Univ. of Mumbai
  • NAAC A++ Contributor (CGPA 3.65)
  • Led 823+ colleges & 54 PG departments
  • Member: Senate, Academic Council & Management Council
Research Output
  • 60+ peer-reviewed publications
  • 1500+ citations (Google Scholar)
  • 13 Government-funded projects
  • Multiple industry collaborations (e.g., Cipla)
Grants & Collaborations
  • β‚Ή3+ Crore research funding
  • BRNS, DBT, DST, UGC funded projects
  • International collaboration: University of Tasmania
  • Industry partnerships and translational projects

Educational Qualifications:

Sr. No.DegreeUniversityYear of Passing
1PhD (Tech.)Mumbai University2006
2M. PharmNagpur University1996
3B. PharmNagpur University1994

Recent Publications: (Best Five in last five years)

Sr. No.Paper Title(Best Five in last five years)Jounal Details
1Nose to brain delivery of flurbiprofen from a solid lipid nanoparticles-based thermosensitive in-situ gelAshok Choudhary, Sakshi Mahajan, Anuradha Majumdar, Nose to brain delivery of flurbiprofen from a solid lipid nanoparticles-based thermosensitive in-situ gel. Neuroscience Applied 3 (2024) 104062
2Network Pharmacology Analysis of Chandraprabha Vati: A New Hope for the Treatment of Metabolic SyndromePrashant Dongre and Anuradha Majumdar, Network Pharmacology Analysis of Chandraprabha Vati: A New Hope for the Treatment of Metabolic Syndrome. February 2024, Journal of Ayurveda and Integrative Medicine, https://doi.org/10.1016/j.jaim.2024.100902, Impact factor: 2.4
3All-trans-retinoic acid and valproic acid: A combinatorial approach for the treatment of nephrotic syndromeCurrent Research in Biotechnology 7 (2024), https://doi.org/10.1016/j.crbiot.2024.100181, Impact factor:
4Green tea as SIRT1 and SIRT3 activator in COVID-19A molecular docking approach, Indian Journal of Natural Products Page 4 of 9 and Resources, Vol. 14(3), September 2023, pp 409-424, DOI: 10.56042/ijnpr.v14i3.5397, Impact factor: 0.192
5Therapeutic potential of endoplasmic reticulum stress inhibitors in the treatment of diabetic peripheral neuropathyMetabolic Brain Disease, https;//doi.org/10.1007/s11011-023-01239-x, Impact factor: 3.584
6Crosstalk between Sirtuins and Nrf2SIRT1 activators as emerging treatment for diabetic neuropathy, Metabolic Brain Disease, https;//doi.org/10.1007/s11011-022-00956-z, Impact factor: 3.584
7Pyrroloquinoline Quinineinhibits PCSK9, augments LDLR recycling and enhances the effect of atorvastatin. bioRxiv preprint doi:https://doi.org/10.1101/2022.03.20.485060
8A new prospect for the treatment of nephrotic syndrome based on network pharmacology analysisCurrent Research in Physiology (2022), Volume 5, Pages 36-47, DOI 10.1016/j.crphys.2021.12.004, Cite score 1.5. (Impact Score 2.42)
9Role of NRF2 and Sirtuin activators in COVID-19, Clinical Immunology 233 (2021) 108879https://doi.org/10.1016/j.clim.2021.108879, Impact Factor: 8.6
10Current Therapies in Nephrotic Syndrome:HDAC Inhibitors, an Emerging Therapy for Kidney Diseases. Current Research in Biotechnology, May 2021, 3(10141), https://doi.org/10.1016/j.crbiot.2021.05.007, Impact factor: 5.6
11Understanding Skin Chronobiology to Unveil and Transform Dermal ChronotherapeuticsPaving the way for the Future. Chronobiology in Medicine, March 2021, 3 (1), DOI: 10.33069/cim.2020.0032
12Melatonin ameliorates neuropathy in diabetic rats by abating mitochondrial dysfunction and metabolic derangementsEndocrine and Metabolic Science 1 (2020) 100067, https://www.sciencedirect.com/science/article/pii/S2666396120300212?via%3Dihub
13Supplementation of pyrroloquinoline quinone with atorvastatin augments mitochondrial biogenesis and attenuates low grade inflammation in obese ratsEuropean Journal of Pharmacology, Volume 881, 15 August 2020, 173273, https://doi.org/10.1016/j.ejphar.2020 (Impact Factor: 5.195)
14Prevention of acute graft-versus-host-disease by Withaferin a via suppression of AKT/mTOR pathway.International Immunopharmacology 84 (2020) 106575, https://doi.org/10.1016/j.intimp.2020.106575 (Impact factor: 5.714)
15Pyrroloquinoline quinone attenuates obesity associated low grade inflammationObesity Medicine 16, 2019, 100134, https://doi.org/10.1016/j.obmed.2019.100134 (Journal impact factor 1.5)
16β€œEnhanced skin permeation of Methotrexate from penetration enhancer containing vesicles: In vitro optimization and in vivo evaluation114: 108770, 2019, Biomedicine and Pharmacotherapy, 114, 2019, DOI https://doi.org/10.1016/j.biopha.2019.108770 (Impact factor: 7.5).
17Microneedles for transdermal drug deliverya systematic review, Drug Development and Industrial Pharmacy, DOI: 10.1080/03639045.2018.1539497 (Impact factor 3.727)

Recent Patents:(ALL)

Sr. No.Patent TitlePatent Number
1A NOVEL PHARMACEUTICAL COMPOSITION OF TOPICAL METHOTREXATE IN CHRONIC INFLAMMATORY CONDITION251524
2Matrix type microneedle patches containing keratolytic agents342562
3Novel composition of micronutrients for protection against non-ionising radiation368640,
4A unique neutraceutical composition to combat colonic inflammation381778
5Combinatorial and chrono-pharmacology guided multi-target integrated holistic combination treatment for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis522398
6A Hyperkeratotic skin penetrating dissolvable microneedle patch and its formulation526934

Trademark

Sr.No.Trademark NameConference Dsetails
1Health HameshaTMDeveloped Mobile and Internet App on Health Information for common citizens in English and many Indian native languages.
2StriShaTMTools including the digital tool such as mobile app to increase awareness on sexual, reproductive, general health, overall wellbeing and the remedial measures. Launched oral contraceptives information app available at play store in June 2023 with feature of pill reminder for improving compliance, Trademark no 5804100 granted 16/06/2024
3CreatinometerTMTrademark no 5870400, granted 10/03/2024
πŸ“§ Contact

πŸ“ Bombay College of Pharmacy, Kalina, Mumbai – 400098

βœ‰οΈ anuradha.majumdar@bcp.edu.in